{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:35:23Z","timestamp":1793392523897,"version":"4.5.0"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"\n Importance<\/jats:title>\n Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy, negatively affecting both mother and child.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To demonstrate the efficacy and safety of zuranolone, a neuroactive steroid \u03b3-aminobutyric acid receptor\u2013positive allosteric modulator, in PPD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This phase 3, double-blind, randomized, outpatient, placebo-controlled clinical trial was conducted between January 2017 and December 2018 in 27 enrolling US sites. Participant were women aged 18 to 45 years, 6 months or fewer post partum, with PPD (major depressive episode beginning third trimester or \u22644 weeks postdelivery), and baseline 17-item Hamilton Rating Scale for Depression (HAMD-17) score of 26 or higher. Analysis was intention to treat and began December 2018 and ended March 2019.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Randomization 1:1 to placebo:zuranolone, 30 mg, administered orally each evening for 2 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary end point was change from baseline in HAMD-17 score for zuranolone vs placebo at day 15. Secondary end points included changes from baseline in HAMD-17 total score at other time points, HAMD-17 response (\u226550% score reduction) and remission (score \u22647) rates, Montgomery-\u00c5sberg Depression Rating Scale score, and Hamilton Rating Scale for Anxiety score. Safety was assessed by adverse events and clinical assessments.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 153 randomized patients, the efficacy set comprised 150 patients (mean [SD] age, 28.3 [5.4] years), and 148 (98.7%) completed treatment. A total of 76 patients were randomized to placebo, and 77 were randomized to zuranolone, 30 mg. Zuranolone demonstrated significant day 15 HAMD-17 score improvements from baseline vs placebo (\u221217.8 vs \u221213.6; difference, \u22124.2; 95% CI, \u22126.9 to \u22121.5;\n P<\/jats:italic>\n \u2009=\u2009.003). Sustained differences in HAMD-17 scores favoring zuranolone were observed from day 3 (difference, \u22122.7; 95% CI, \u22125.1 to \u22120.3;\n P<\/jats:italic>\n \u2009=\u2009.03) through day 45 (difference, \u22124.1; 95% CI, \u22126.7 to \u22121.4;\n P<\/jats:italic>\n \u2009=\u2009.003). Sustained differences at day 15 favoring zuranolone were observed in HAMD-17 response (odds ratio, 2.63; 95% CI, 1.34-5.16;\n P<\/jats:italic>\n \u2009=\u2009.005), HAMD-17 score remission (odds ratio, 2.53; 95% CI, 1.24-5.17;\n P<\/jats:italic>\n \u2009=\u2009.01), change from baseline for Montgomery-\u00c5sberg Depression Rating Scale score (difference, \u22124.6; 95% CI, \u22128.3 to \u22120.8;\n P<\/jats:italic>\n \u2009=\u2009.02), and Hamilton Rating Scale for Anxiety score (difference, \u22123.9; 95% CI, \u22126.7 to \u22121.1;\n P<\/jats:italic>\n \u2009=\u2009.006). One patient per group experienced a serious adverse event (confusional state in the zuranolone group and pancreatitis in the placebo group). One patient in the zuranolone group discontinued because of an adverse event vs none for placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, zuranolone improved the core symptoms of depression as measured by HAMD-17 scores in women with PPD and was generally well tolerated, supporting further development of zuranolone in the treatment of PPD.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02978326<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2021.1559","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T14:39:15Z","timestamp":1625063955000},"page":"951","source":"Crossref","is-referenced-by-count":268,"title":["Effect of Zuranolone vs Placebo in Postpartum Depression"],"prefix":"10.1001","volume":"78","author":[{"given":"Kristina M.","family":"Deligiannidis","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York"},{"name":"Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Meltzer-Brody","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handan","family":"Gunduz-Bruce","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Doherty","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jonas","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigui","family":"Li","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul J.","family":"Sankoh","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Silber","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Werneburg","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kanes","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lasser","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"19","key":"yoi210036r3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.15585\/mmwr.mm6919a2","article-title":"Vital signs: postpartum depressive symptoms and provider discussions about perinatal depression: United States, 2018.","volume":"69","author":"Bauman","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"yoi210036r5","doi-asserted-by":"publisher","DOI":"10.5888\/pcd11.130415","article-title":"Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010.","volume":"11","author":"DeSisto","year":"2014","journal-title":"Prev Chronic Dis"},{"issue":"5","key":"yoi210036r8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/01.AOG.0000437382.03963.88","article-title":"Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy.","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"4","key":"yoi210036r9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ajog.2010.01.011","article-title":"Trends in postpartum hemorrhage: United States, 1994-2006.","volume":"202","author":"Callaghan","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"yoi210036r10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.4088\/JCP.15r10174","article-title":"The perinatal depression treatment cascade: baby steps toward improving outcomes.","volume":"77","author":"Cox","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"yoi210036r11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-019-00605-7","article-title":"Pharmacotherapy of postpartum depression: current approaches and novel drug development.","volume":"33","author":"Frieder","year":"2019","journal-title":"CNS Drugs"},{"issue":"3","key":"yoi210036r12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapsychiatry.2017.4363","article-title":"Association of persistent and severe postnatal depression with child outcomes.","volume":"75","author":"Netsi","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi210036r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HRP.0000000000000013","article-title":"The course of postpartum depression: a review of longitudinal studies.","volume":"22","author":"Vliegen","year":"2014","journal-title":"Harv Rev Psychiatry"},{"issue":"6","key":"yoi210036r14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1176\/appi.ajp.2015.14121510","article-title":"All-cause mortality in women with severe postpartum psychiatric disorders.","volume":"173","author":"Johannsen","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"12","key":"yoi210036r15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1089\/jwh.2015.5346","article-title":"Suicidal ideation during the postpartum period.","volume":"25","author":"Bodnar-Deren","year":"2016","journal-title":"J Womens Health (Larchmt)"},{"issue":"2","key":"yoi210036r16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/wps.v13.2","article-title":"Risks of all-cause and suicide mortality in mental disorders: a meta-review.","volume":"13","author":"Chesney","year":"2014","journal-title":"World Psychiatry"},{"issue":"8","key":"yoi210036r17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00127-012-0636-0","article-title":"Antenatal and postnatal maternal mental health as determinants of infant neurodevelopment at 18 months of age in a mother-child cohort (Rhea Study) in Crete, Greece.","volume":"48","author":"Koutra","year":"2013","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"12","key":"yoi210036r18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamapsychiatry.2013.2163","article-title":"Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years.","volume":"70","author":"Pearson","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"yoi210036r19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1471-2431-14-185","article-title":"Early maternal depressive symptoms and child growth trajectories: a longitudinal analysis of a nationally representative US birth cohort.","volume":"14","author":"Surkan","year":"2014","journal-title":"BMC Pediatr"},{"issue":"pt A","key":"yoi210036r20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.infbeh.2016.10.001","article-title":"Association between maternal postnatal depressive symptoms and infants' communication skills: a longitudinal study.","volume":"45","author":"Valla","year":"2016","journal-title":"Infant Behav Dev"},{"issue":"6","key":"yoi210036r21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2215-0366(14)70361-X","article-title":"Postnatal depressive symptoms and child psychological development at 10 years: a prospective study of longitudinal data from the South African Birth to Twenty cohort.","volume":"1","author":"Verkuijl","year":"2014","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi210036r22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00737-015-0562-8","article-title":"Maternal depression from pregnancy to 4 years postpartum and emotional\/behavioural difficulties in children: results from a prospective pregnancy cohort study.","volume":"19","author":"Woolhouse","year":"2016","journal-title":"Arch Womens Ment Health"},{"issue":"1","key":"yoi210036r23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1365-2648.2003.02857.x","article-title":"Paternal postpartum depression, its relationship to maternal postpartum depression, and implications for family health.","volume":"45","author":"Goodman","year":"2004","journal-title":"J Adv Nurs"},{"issue":"2","key":"yoi210036r24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0165-0327(99)00159-7","article-title":"Paternal and maternal depressed mood during the transition to parenthood.","volume":"60","author":"Matthey","year":"2000","journal-title":"J Affect Disord"},{"key":"yoi210036r25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fpsyg.2016.00938","article-title":"Perinatal parenting stress, anxiety, and depression outcomes in first-time mothers and fathers: a 3- to 6-months postpartum follow-up Study.","volume":"7","author":"Vismara","year":"2016","journal-title":"Front Psychol"},{"key":"yoi210036r26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yfrne.2018.12.001","article-title":"Pathophysiological mechanisms implicated in postpartum depression.","volume":"52","author":"Payne","year":"2019","journal-title":"Front Neuroendocrinol"},{"issue":"10","key":"yoi210036r27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11920-017-0824-4","article-title":"Understanding peripartum depression through neuroimaging: a review of structural and functional connectivity and molecular imaging research.","volume":"19","author":"Duan","year":"2017","journal-title":"Curr Psychiatry Rep"},{"key":"yoi210036r28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fncel.2019.00083","article-title":"Neuroactive steroids and GABAergic involvement in the neuroendocrine dysfunction associated with major depressive disorder and postpartum depression.","volume":"13","author":"Maguire","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"yoi210036r29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.psyneuen.2017.02.012","article-title":"Lower allopregnanolone during pregnancy predicts postpartum depression: an exploratory study.","volume":"79","author":"Osborne","year":"2017","journal-title":"Psychoneuroendocrinology"},{"issue":"7","key":"yoi210036r30","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1210\/jcem.85.7.6675","article-title":"Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients.","volume":"85","author":"Luisi","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"yoi210036r31","first-page":"77","article-title":"Serum allopregnanolone in women with postpartum \u201cblues\u201d.","volume":"97","author":"Nappi","year":"2001","journal-title":"Obstet Gynecol"},{"key":"yoi210036r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.104827","article-title":"Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: a liquid chromatography-tandem mass spectrometry analysis.","volume":"121","author":"Deligiannidis","year":"2020","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"yoi210036r33","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41386-018-0242-2","article-title":"Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic resonance imaging and spectroscopy study.","volume":"44","author":"Deligiannidis","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"yoi210036r34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuron.2008.06.019","article-title":"GABA(A)R plasticity during pregnancy: relevance to postpartum depression.","volume":"59","author":"Maguire","year":"2008","journal-title":"Neuron"},{"key":"yoi210036r35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.psyneuen.2017.12.003","article-title":"Inability to suppress the stress-induced activation of the HPA axis during the peripartum period engenders deficits in postpartum behaviors in mice.","volume":"90","author":"Mel\u00f3n","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"yoi210036r36","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3389\/fendo.2018.00703","article-title":"A novel, synthetic, neuroactive steroid is effective at decreasing depression-like behaviors and improving maternal care in preclinical models of postpartum depression.","volume":"9","author":"Mel\u00f3n","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10093","key":"yoi210036r37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"issue":"10152","key":"yoi210036r38","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"yoi210036r39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies.","volume":"59","author":"Hoffmann","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"yoi210036r40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nsmb.3477","article-title":"Crystal structures of a GABAA-receptor chimera reveal new endogenous neurosteroid-binding sites.","volume":"24","author":"Laverty","year":"2017","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"yoi210036r41","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1096\/fsb2.v6.6","article-title":"Neuroactive steroids.","volume":"6","author":"Paul","year":"1992","journal-title":"FASEB J"},{"issue":"18","key":"yoi210036r42","doi-asserted-by":"publisher","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive Steroids: 2: 3a-Hydroxy-3\u00df-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5\u00df-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (?-Aminobutyric Acid)A receptor.","volume":"60","author":"Martinez Botella","year":"2017","journal-title":"J Med Chem"},{"issue":"20","key":"yoi210036r43","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"yoi210036r44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"yoi210036r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator.","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"yoi210036r46","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"1","key":"yoi210036r47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/papt.1959.32.issue-1","article-title":"The assessment of anxiety states by rating.","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"issue":"9","key":"yoi210036r48","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","article-title":"Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence.","volume":"48","author":"Frank","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"yoi210036r49","first-page":"5","article-title":"Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.","volume":"62","author":"Nierenberg","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"yoi210036r51","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1089\/jwh.2009.1893","article-title":"Development of the Barkin Index of Maternal Functioning.","volume":"19","author":"Barkin","year":"2010","journal-title":"J Womens Health (Larchmt)"},{"issue":"12","key":"yoi210036r52","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi210036r53","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2576","article-title":"Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.","volume":"32","author":"Kanes","year":"2017","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"yoi210036r54","doi-asserted-by":"publisher","first-page":"946","DOI":"10.4088\/JCP.v69n0610","article-title":"Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.","volume":"69","author":"Machado-Vieira","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"yoi210036r55","article-title":"Antidepressant treatment for postnatal depression.","author":"Molyneaux","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"yoi210036r56","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi210036r57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"yoi210036r58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jad.2013.09.019","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials.","volume":"152-154","author":"De Crescenzo","year":"2014","journal-title":"J Affect Disord"},{"issue":"1","key":"yoi210036r59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.20471\/acc.2018.57.01.05","article-title":"Anxiety during pregnancy and postpartum: course, predictors and comorbidity with postpartum depression.","volume":"57","author":"Nakic Rado\u0161","year":"2018","journal-title":"Acta Clin Croat"},{"issue":"3","key":"yoi210036r60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/01.nmd.0000258229.38212.6f","article-title":"Comparison of quality of life measures in a depressed population.","volume":"195","author":"Wisniewski","year":"2007","journal-title":"J Nerv Ment Dis"},{"key":"yoi210036r1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"yoi210036r4","volume-title":"Vital Statistics Rapid Release: Births: Provisional Data for 2018: Report No. 007","author":"Hamilton","year":"2018"},{"key":"yoi210036r50","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"yoi210036r2","unstructured":"National Institute of Mental Health. Perinatal depression. Accessed February 8, 2021. https:\/\/www.nimh.nih.gov\/health\/publications\/postpartum-depression-facts\/index.shtml"},{"key":"yoi210036r6","unstructured":"Centers for Disease Control and Prevention. Diabetes during pregnancy. Updated June 12, 2018. Accessed February 8, 2021. https:\/\/www.cdc.gov\/reproductivehealth\/maternalinfanthealth\/diabetes-during-pregnancy.htm"},{"key":"yoi210036r7","unstructured":"Centers for Disease Control and Prevention. Data on selected pregnancy complications in the United States. Updated February 28, 2019. Accessed February 8, 2021. https:\/\/www.cdc.gov\/reproductivehealth\/maternalinfanthealth\/pregnancy-complications-data.htm"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2781385\/jamapsychiatry_deligiannidis_2021_oi_210036_1669133790.10656.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T11:00:32Z","timestamp":1669806032000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2781385"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.1559","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740396617.793593406","asserted-by":"object"}]},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}